Nonalcoholic steatohepatitis (NASH) Solutions Overview Date Published: Aug 12, 2021 Brochure The prevalence of nonalcoholic steatohepatitis (NASH) is expected to increase in the near future, making it all the more important to develop effective, new treatments. With Signant’s SmartSignals™ solutions you can: Collect accurate patient-reported outcomes & objective activity data Educate & engage patients Assess cognitive functions Offer flexible, remote participation options Download Now Share: LinkedInTweet